How does RWE meet the value requirements from EU payers?
Now and in the future.
On-demand webinar: How does RWE meet the value requirements from EU payers – now and in the future?
- Health Technology Assessment (HTA) bodies recognize the importance of real world evidence (RWE) to address uncertainties as they evaluate the effectiveness of new drugs. However, to date, RWE has had a limited impact on HTA decision-making. This panel will discuss the path forward to increase the inclusion of RWE in HTA and decision-making.
Fact sheet: HTA accelerator informs strategic market access decisions
- Anticipating market access dynamics and developing the necessary evidence requires a nuanced understanding of the market access landscape. IQVIA’s HTA Accelerator offers an integrated solution providing market access insights from Phase II development to post-launch.
Whitepaper: Launch Excellence VII: The three pillars of post-pandemic launch excellence
- The Launch Excellence environment changed dramatically and comprehensively in the last year. To respond, we’ve divided our launch cohort into a pre-pandemic cohort, which we have followed for 18 months of performance unaffected by the pandemic, and the launches from late 2019, which have launched into the pandemic during part or all of their crucial first six months on the market, evaluating those launches for their first six months.
Explore how to leverage RWE for your business.
Let’s talk. Please complete the form below.
Copyright © 2025 IQVIA Holdings Inc. and its affiliates. All rights reserved. Privacy Statement
